Agile Therapeutics (AGRX)
(Delayed Data from OTC)
$1.47 USD
0.00 (0.00%)
Updated Aug 2, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AGRX 1.47 0.00(0.00%)
Will AGRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AGRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGRX
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
AGRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?
Is Ardelyx (ARDX) Outperforming Other Medical Stocks This Year?
Other News for AGRX
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics Merges with Insud Pharma Subsidiary
Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M
Agile Therapeutics to be acquired by Insud Pharma for $1.52 per share in cash
Agile Therapeutics: Q1 Earnings Snapshot